What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.

Patrice Matchaba shares how a lifetime of experience helped shape an effort to address healthcare disparities.

Lutz Hegemann shares how lessons learned treating patients with leprosy influenced the way he thinks about the pharmaceutical business.

COPD receives low attention as a women’s health issue. It’s time to change that.

Novartis is working to tackle the problem of counterfeit drugs, which are a threat to patient health.

Jean Silveri shares key insights from her legal career.